192 related articles for article (PubMed ID: 32600804)
1. Measurement of pholcodine-specific IgE in addition to morphine-specific IgE improves investigation of neuromuscular blocking agent anaphylaxis.
Anderson J; Green S; Capon M; Krupowicz B; Li J; Fulton R; Fernando SL
Br J Anaesth; 2020 Dec; 125(6):e450-e452. PubMed ID: 32600804
[No Abstract] [Full Text] [Related]
2. Morphine and pholcodine-specific IgE have limited utility in the diagnosis of anaphylaxis to benzylisoquinolines.
Rose MA; Anderson J; Green SL; Yun J; Fernando SL
Acta Anaesthesiol Scand; 2018 May; 62(5):628-634. PubMed ID: 29368335
[TBL] [Abstract][Full Text] [Related]
3. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents.
Harboe T; Johansson SG; Florvaag E; Oman H
Allergy; 2007 Dec; 62(12):1445-50. PubMed ID: 17983379
[TBL] [Abstract][Full Text] [Related]
4. IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: Lessons from flow cytometry.
Leysen J; De Witte L; Sabato V; Faber M; Hagendorens M; Bridts C; De Clerck L; Ebo D
Cytometry B Clin Cytom; 2013 Mar; 84(2):65-70. PubMed ID: 23355309
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of morphine, pholcodine and poppy seed IgE assays in drug-abusers and allergic people.
Armentia A; Ruiz-Muñoz P; Quesada JM; Postigo I; Herrero M; Martín-Gil FJ; Gonzalez-Sagrado M; Martín B; Castrodeza J
Allergol Immunopathol (Madr); 2013; 41(1):37-44. PubMed ID: 21940094
[TBL] [Abstract][Full Text] [Related]
6. Pholcodine and allergy to neuromuscular blocking agents: where are we and how did we get here?
Savic L; Hopkins PM
Br J Anaesth; 2024 Mar; 132(3):457-460. PubMed ID: 38071149
[TBL] [Abstract][Full Text] [Related]
7. Pholcodine caused anaphylaxis in Sweden 30 years ago.
Johansson SG; Oman H; Nopp A; Florvaag E
Allergy; 2009 May; 64(5):820-1. PubMed ID: 19210354
[No Abstract] [Full Text] [Related]
8. Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis.
Brusch AM; Clarke RC; Platt PR; Phillips EJ
Br J Clin Pharmacol; 2014 Jul; 78(1):14-23. PubMed ID: 24251966
[TBL] [Abstract][Full Text] [Related]
9. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market.
Florvaag E; Johansson SG; Irgens Å; de Pater GH
Allergy; 2011 Jul; 66(7):955-60. PubMed ID: 21241314
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin E antibodies to rocuronium: a new diagnostic tool.
Ebo DG; Venemalm L; Bridts CH; Degerbeck F; Hagberg H; De Clerck LS; Stevens WJ
Anesthesiology; 2007 Aug; 107(2):253-9. PubMed ID: 17667569
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively.
Florvaag E; Johansson SG; Oman H; Venemalm L; Degerbeck F; Dybendal T; Lundberg M
Acta Anaesthesiol Scand; 2005 Apr; 49(4):437-44. PubMed ID: 15777289
[TBL] [Abstract][Full Text] [Related]
12. Opioid non-IgE mediated effects in a BAT assay on drug hypersensitivity to pholcodine.
Chirumbolo S
Cytometry B Clin Cytom; 2014 Mar; 86(2):77. PubMed ID: 24030936
[No Abstract] [Full Text] [Related]
13. Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents.
de Pater GH; Florvaag E; Johansson SG; Irgens Å; Petersen MN; Guttormsen AB
Allergy; 2017 May; 72(5):813-819. PubMed ID: 27859358
[TBL] [Abstract][Full Text] [Related]
14. Morphine-specific IgE testing in the assessment of neuromuscular blocking agent allergy: a single centre experience.
Chow KL; Patchett K; Reeves G; de Malmanche T; Gillies D; Boyle M
Br J Anaesth; 2024 Jan; 132(1):193-195. PubMed ID: 37945415
[No Abstract] [Full Text] [Related]
15. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study.
Johansson SG; Florvaag E; Oman H; Poulsen LK; Mertes PM; Harper NJ; Garvey LH; Gerth van Wijk R; Metso T; Irgens A; Dybendal T; Halsey J; Seneviratne SL; Guttormsen AB
Allergy; 2010 Apr; 65(4):498-502. PubMed ID: 19796197
[TBL] [Abstract][Full Text] [Related]
16. Response to letter regarding article 'Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis'.
Brusch AM; Clarke RC; Platt PR; Phillips E
Br J Clin Pharmacol; 2014 Oct; 78(4):931-2. PubMed ID: 24611979
[No Abstract] [Full Text] [Related]
17. [Correlation between pholcodine and perioperative anaphylaxis].
Dumancić J; Marković AS
Acta Med Croatica; 2012 May; 66(2):111-4. PubMed ID: 23437637
[TBL] [Abstract][Full Text] [Related]
18. IgE-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?
Florvaag E; Johansson SG
Curr Allergy Asthma Rep; 2008 Sep; 8(5):375-6. PubMed ID: 18682099
[No Abstract] [Full Text] [Related]
19. Stability of a 1.0 mg ml(-1) aqueous pholcodine solution for allergy skin testing.
Barbier P; Scala-Bertola J; Gambier N; Rivier A; Demoré B; Gillet P; Nicolas A; Petitpain N
Br J Clin Pharmacol; 2014 Nov; 78(5):1172-4. PubMed ID: 24903072
[No Abstract] [Full Text] [Related]
20. The pholcodine story.
Florvaag E; Johansson SG
Immunol Allergy Clin North Am; 2009 Aug; 29(3):419-27. PubMed ID: 19563989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
